Article

[Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages].

Wojewódzki Szpital Zakainy w Warszawie.
Przegla̧d epidemiologiczny 01/2006; 60(4):673-6. pp.673-6
Source: PubMed

ABSTRACT Early virologic response (EVR) depending on various hepatic fibrosis was analyzed at 12 week of pegylated interferon alfa-2b (Pegintron, 12 KD) with ribavirin treatment among chronic hepatitis C patients (pts) infected with genotype non 2/3. The A group composed 29 pts. They were of staging 0 and grading 1. The group B composed 47 pts of staging 1, C 33 pts of staging 2, D 35 pts of staging 3 and 4. Liver biopsies were analyzed according to the Scheuer's and Knodell's scores. Early virologic response (ERV) was defined as decrease of VL >2 log or undetectable HCV RNA. Viral load (VL) was determined with HCV RNA Assay and CA HCV Monitor Test (Roche Diagn. Sys.). The EVR rates for the A, B, C, D groups were as follow: 86,2% (25/29), 80,9% (38/47), 75,8% (25/33) and 60% (15/25), respectively.

0 0
 · 
0 Bookmarks
 · 
15 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

chronic hepatitis C patients
 
decrease
 
genotype non 2/3
 
group B
 
HCV Monitor Test
 
HCV RNA Assay
 
Knodell's scores
 
Liver biopsies
 
pegylated interferon alfa-2b
 
pts
 
ribavirin treatment
 
Roche Diagn
 
Scheuer's
 
undetectable HCV RNA
 
various hepatic fibrosis
 
virologic response